Developing the latest framework to measure and incentivise pharmaceutical industry action on R&D

The global health community has identified priority targets for pharmaceutical R&D. The Index will analyse R&D pipelines for all these targets, as set out in a new article published in Health Research Policy and Systems.

Major pharmaceutical companies contribute important expertise to health research and development (R&D), particularly in their ability to develop and bring pharmaceuticals to market.

This article sets out how the research team for the Access to Medicine Index identified the priorities for these companies when it comes to directing R&D efforts towards the needs of people living in low- and middle-income countries.

Two main changes to the methodology were made that will further deepen the Index’s analysis of (1) how far companies’ R&D activity aligns with global health priorities; and (2) whether companies make plans to ensure resulting innovations reach populations in need globally. These changes will be applied in the 2018 Access to Medicine Index.

Stanford Social Innovation Review: Access by Prescription

In the article, Jayasree K. Iyer, Executive Director at the Access to Medicine Foundation, describes the corporate strategies that large pharmaceutical companies use to make medicines and vaccines accessible for people living in low- and middle-income countries. In this piece, she identifies the steps that companies can and typically do take when creating an effective access-to-medicine strategy.

Developing the latest framework to measure and incentivise pharmaceutical industry action on R&D

Explore further

New paper explains expanded Index focus on global health R&D

Stanford Social Innovation Review: Access by Prescription

Index added to new online toolbox for impact investors